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ABSTRACT 
A microsponge delivery system will entrap a wide variety of active pharmaceutical ingredients and then release them onto the skin over a time 
and additionally in response to different stimuli including rubbing, moisture, pH, friction, or ambient skin temperature. It can also be used for 
controlled oral delivery of drugs using water-soluble, water-insoluble and bio-erodible polymers. The primary aim of any drug delivery system 
is to provide a therapeutic quantity of drug to the suitable site in the body, to punctually achieve and retain the desired drug concentration. The 
elemental application of the microsponge technology arises as of the difficulty experienced with predictable formulations in release active 
ingredients over an extended period of time. Microsponges also enhanced bioavailability of active ingredient and increase the solubility of the 
poorly water-soluble drug. Microsponge is providing some advantages like controlled release and extended release of active agents by using  
different polymers. They become a reduced irritation and improved thermal, physical, and chemical stability of the product. The pre sent review 
describes microsponge technology including its method of preparation, characterization, programmable parameters and release mechanism of 
microsponge drug delivery system. Microsponges can be designed to programmable release of drug by using different triggers li ke solubility 
triggered systems, pressure triggered systems, temperature triggered systems and pH triggered systems. 
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INTRODUCTION 
To control the delivery rate of active agents to a 
predetermined site in the human body has been one of the 
greatest challenges faced by the pharmaceutical industry. To 
the controlled release of drug from the formulation into the 
epidermis such that the drug remains primarily localized 
with only a limited amount entering the systemic circulation 
is a means of controlling side-effects. Another prospective 
difficulty in the topical delivery of drugs relates to the use of 
unaesthetic vehicles which may be greasy, sticky and may 
cause discolorations since this can result reduce patient 
compliance. The vehicles of topical formulations need to 
hold high concentrations of active agents for useful therapy 
because of the low efficiency of the delivery system, 
consequential into irritation and allergic reactions in 
significant users. Other disadvantages of topical 
formulations are uncontrolled evaporation of active 
ingredient, potential incompatibility and obnoxious odour of 
drugs with the vehicles. Thus there is a requirement to 
maximize the amount of time that an active ingredient is 
present either on the skin surface or within the epidermis 
while minimizing its transdermal penetration into the body. 
Several predictable and reliable systems were developed for 
systemic drugs under the heading of the transdermal 
delivery system (TDS) using the skin as a portal of entry. It 
has improved the efficacy and safety of many drugs that may 
be better administered through the skin. But TDS is not 
practical for delivery of materials whose final target is skin 
itself. Further, these porous microspheres with active 
ingredients can be incorporated into formulations such as 
creams, lotions, and powders. The release of the drug into 
the skin is initiated by a variety of triggers, including 
rubbing and higher than ambient skin temperature.[1] 
The microsponge technology was developed by Won in 1987 
and the original patents were assigned to advanced polymer 
system, Inc. At current, this technology has been licensed to 
Cardinal Health, Inc., for use in topical products.[2] 
Microsponges are tiny, sponge-like spherical particles that 
consist of a myriad of interconnecting voids within a non-
collapsible structure with a large porous surface through 
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which active ingredients are released in a controlled 
manner. These microsponges have the capacity to entrap a 
wide range of active ingredients such as emollients, 
fragrances, essential oils, sunscreens and anti-infective and 
used as a carrier for topical drug delivery.[3,4] To control 
the delivery rate of the drug to a predetermined site in the 
human body has been one of the greatest challenges 
followed by pharmaceutical researchers. Controlled release 
of active ingredient onto the epidermis with an assurance 
that the drug remains primarily localized and does not enter 
the systemic circulation in significant quality is a challenging 
area of research.[5] 
Defining microsponge: 
The microsponge delivery system is a patented polymeric 
system consisting of porous microspheres. They are tiny 
sponge like spherical particles that consist of a myriad of 
interconnecting voids within a non-collapsible structure 
with a large porous surface through which active ingredient 
are release in a controlled manner. The size of microsponge 
ranges from 5-300   in diameter and a typical 25   sphere 
can have up to 250000 pores and an internal pore structure 
equivalent to 10 feet in length, providing a total pore volume 
of about 1 ml/g for extensive drug retention. The surface can 
be varied from 20-500 m2/g and pore volume range from 
0.1-0.3cm3/g. This is results in large reservoir within each 
microsponge, which can be loaded with up to its own weight 
of active agent. [6] 
Structure:  
Microsponges are uniform, spherical, porous polymeric 
microspheres having myriad of interconnecting voids of 
particle size range 5-300  (fig 1). These microspheres 
having the capacity to entrap a wide range of active 
ingredients such as emollients, fragrance, essential oils, 
sunscreens and anti-infective, etc. are as a topical carrier 
system. Microspheres, averaging 25   in diameter and 
embedded in a vehicle, act like microscopic sponge, storing 
the active drug until its release is triggered by application to 
the skin surface. Micropores within the spheres comprise a 
total pore density of approximately 1ml/g, and pore length 
10 ft for extensive drug retention. Further this porous 
microsphere with active ingredient can be incorporated in to 
formulation such as creams, lotions, and powders. 
Microsponge consist of non-collapsible structure with 
porous surface through active ingredient are release in 
controlled manner. Release of the drug into the skin is 
initiated by a variety of triggers, including rubbing and 
higher than ambient skin temperature. There is high degree 
of cross-linking result in particle that are insoluble, inert and 
of sufficient strength to stand up to the high shear commonly 
used in manufacturing of creams, lotions and powders. Their 
characteristics feature is the capacity to absorb or load a 
high degree of active materials into the particle and on to its 
surface. Its large capacity for entrapment of actives, up to 
three times of its weight, differentiates microsponge product 
from other types of dermatological delivery system. The 
active payload is protected in the formulation by the 
microsponge particles. It’s delivered to the skin via 
controlled diffusion. This sustained release of actives to skin 
over time is an extremely valuable tool to extend the efficacy 
and lessen the irritation commonly associated with powerful 
therapeutic agent like  -hyroxy acid which may produce 
burning, stinging or redness in individual with sensitive skin. 
Microsponge polymers possess the versatility to load a wide 
range of actives providing the benefits enhanced product 
efficacy, mildness, tolerability, and extended wear to a wide 
range of skin therapies. When microsponge delivery system 
applied to the skin, the release of drug can be controlled 
through diffusion or other variety of triggers, include 
rubbing, moisture, pH, friction, or ambient skin temperature. 
[7] 
 
[Source: IJPRA 2012; 2(2): 82] 
Fig 1: Highly porous nature of Microsponge.[1] 
Advantages: 
 Advanced oil control, absorb up to 6th times its weight 
without drying. 
 Reduce irritation formula. 
 Allows novel product form. 
 Extended release, continuous action up to 12 hours. 
 Reduce irritation, better tolerance means broader 
consumer acceptance.  
 Improves product aesthetics, gives product and elegant 
feel. 
 Improves stability, thermal, physical and chemical 
stability. 
 Allowed incorporation of immiscible products. 
 Improves material processing e.g. Liquid can be 
converted to the powders. 
 Allows for novel product forms. 
 Improves efficacy in treatment. 
 Cure or control confirm more promptly. 
 Improve control of condition. 
 Improve bioavailability of same drugs.[8] 
Characteristics of microsponge:  
 These formulations are stable over range of pH 1 to 11 
 These formulations are   stable   at   the   temperature 
up to 130 .  
 These formulations are compatible with most vehicles 
and ingredients  
 These are self-sterilizing as their average pore size is 
0.25μm where bacteria cannot penetrate 
 These formulations are free flowing and can be cost 
effective.[9] 
 Microsponge formulation have higher payload (50-
60%), still free flowing and can be cost effective.[10] 
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Characteristics of the active moieties that is entrapped 
into microsponge: 
 Active ingredients that are entrapped in microsponge 
can then be incorporated in to the many products such 
as creams, gels, powders, lotions and soaps. 
 Certain considerations are taken into account while, 
formulating the vehicle in order to achieve desired 
product characteristics. 
 It should be either fully miscible in monomer as well as 
capable of being made miscible by addition of small 
amount of a water immiscible solvent. 
 It should be inert to monomers and should not 
increase the viscosity of the mixture during 
formulation. 
 It should be water immiscible or nearly only slightly 
soluble. 
 It should not collapsed spherical structure of the 
microsponges. 
 It should be stable in contact with polymerization 
catalyst and also in conditions of polymerization. 
 The solubility of actives in the vehicles must be limited. 
 If not, the vehicle will deplete the microsponges before 
the application. 
 Not more then 10-12% w/w microsponges must be 
incorporated into the vehicle in order to avoid 
cosmetic problems. 
 Payload and polymer design of the microsponges for 
the active must be optimized for required release rate 
for given period of time.[11] 
Formulations: [12-20] The MDS contain drug, polymer, 
vehicle and other additives like plasticizers that helps 
stabilize the structure. Various drugs used in microsponge 
drug delivery system are as follows: 
 Domperidone 
 Chlorpheniramine Maleate, 
 Fluconazole, 
 Benzoyl Peroxide, 
 Indomethacin, 
 Dicyclomine, 
 Diclofenac Sodium, 
 Lornoxicam Microsponge, 
 Pantoprazole. 
Preparation of microsponges: 
Drug entrapped in microsponges can take place in two ways, 
based on physicochemical properties of drug. One step 
process and two-step process with respective liquid-liquid 
suspension polymerization and quasi emulsion solvent 
diffusion techniques. If the drug is typically and inert non 
polar material will create porous structure it is called 
porogen. Porogen drug, which neither hinders the 
polymerization nor become activated by it and stable to free 
radical entrapped with one step process. 
A. Quasi emulsion solvent diffusion evaporation 
method: 
The microsponges also prepared by a quasi solvent diffusion 
method by two step process(top-down approach: starting 
with performed polymer) using and external phase of 
containing 200ml of distilled water and 40mg polyvinyl 
alcohol (PVA) 72000. The internal phase consisted of drug, 
ethyl alcohol, polymer and tri-ethylcitrate (TEC), which was 
added at an amount of 20% of the polymer in order to 
facilitate the plasticity. At first, the internal phase was 
prepared at 60  and added to the external phase at room 
temperature. After emulsification, the mixture was 
continuously stirred for two hours. Then the mixture was 
filtered to separate the microsponges. The product was 
washed and dried by vacuum oven at 40  for 24hrs. (Shown 
in fig. 2)[7] 
 
 
[Source: IJPSRR 2011; 8(2): 14-15] 
Fig. 2: Quasi emulsion solvent diffusion evaporation method.[11] 
Darekar et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):793-801 
ISSN: 2250-1177                                                                                [796]                                                                                       CODEN (USA): JDDTAO 
B. Liquid-liquid suspension polymerization: 
The porous microspheres are prepared by suspension 
polymerization method in liquid-liquid systems. In their 
preparation, the monomers are first dissolved along with 
active ingredients in a suitable solvent solution of monomer 
and are then dispersed in the aqueous phase, which consist 
of additives (surfactant, suspending agents etc.). The 
polymerization is then initiated by adding catalyst or by 
increasing temperature or irradiation rate for given time 
period. Monomer or combinations of monomers are selected 
and polymerization begins to form chain monomers as a 
result of cross linking ladders are formed between chains of 
monomer. Monomer ladder are folded to form spherical 
particles i.e. agglomeration of microspheres, which give rise 
to formation of bunches of microspheres. Binding of bunches 
to form microsponges, a reservoir type of system, which 
opens at the surface through pores. Some time inert liquid 
immiscible with water but completely miscible with 
monomer is used during the polymerization to form the pore 
network. After the polymerization the liquid is removed 
leaving the porous microspheres, i.e. Microsponges, solvent 
may be used for faster and efficient incorporation of the drug 
substances. Reaction vessel of microsponges preparation by 
liquid-liquid suspension Polymerization (shown in fig.3). 
[21]
 
 
[Source: IJPSRR 2011; 8(2): 14-15.] 
Fig. 3: Liquid-liquid suspension polymerization method 
Table 1: The various steps summarized: [7] 
Step 1: Selection of monomer or combination of monomers. 
Step 2: Formation of chain monomers as polymerization begins. 
Step 3: Formation of ladders as a result of cross linking between chain monomers. 
Step 4: Folding of monomer ladder to form spherical particles. 
Step 5: Agglomeration of microspheres, which give rise to formation, bunches of microspheres. 
Step 6: Binding of bunches to form microsponges. 
 
RELEASE MECHANISM 
Programmable drug release: Microsponges can be 
designed to release given amount of active ingredients over 
time in response to one or more external triggers. 
 Pressure triggered systems: 
Microsponges system releases the entrapped material when 
pressurized/rubbed; the amount released depends upon 
various characteristics of the sponge. By varying the type of 
material and different process variables, the microsponge 
best suited for a given application may be optimized. When 
compared with mineral oil-containing microcapsules, 
mineral oil containing microsponge showed much more 
softening effect. The duration of emolliency was also much 
more for the microsponge systems. 
 Temperature-triggered systems:  
Some entrapped active ingredients can be too viscous at 
room temperature to flow spontaneously from microsponge 
onto the skin. Increased in skin temperature can result in an 
increased flow rate and hence release. So it is possible to 
modulate the release of substances from the microsponge by 
modulation of temperature. For example, viscous sunscreens 
were found to show a higher release from microsponge 
when exposed to higher temperatures; thus a sunscreen 
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would be released from a microsponge only upon exposure 
to the heat from the sun. 
 pH triggered systems:  
Triggering the pH-based release of the active can be 
achieved by modifying the coating on the microsponge. This 
has many applications in drug delivery.  
 Solubility triggered systems:  
Presence of an aqueous medium such as perspiration can 
trigger the release rate of active ingredients. Ingredients 
such as antiseptics, deodorants and antiperspirants may be 
formulated in such types of systems. Release may be 
achieved based on the ability of the external medium to 
dissolve the active, the concentration gradient or the ability 
to swell the microsponge network. [22] 
EVALUATION PARAMETERS OF MICROSPONGES 
 Particle size (Microscopy). 
 Morphology and Surface topography. 
 Loading efficiency and production yield. 
 Compatibility studies. 
 Resiliency. 
 Dissolution Studies. 
 Kinetics of release. 
 Determination of true density. 
 Characterization of pore structure. 
 Particle Size Determination: Particle  size  analysis  
of   loaded  and  unloaded  microsponges  can  be  
performed by  laser light diffractometry or any other 
suitable method. The values can be expressed for all 
formulations as mean particle size range. Cumulative 
percentage drug release from microsponges of 
different particle size will be plotted against time to 
study effect of particle size on drug release.   
 Morphology and Surface Topography of 
Microsponges: For  morphology  and  surface  
topography,  prepared  microsponges  can  be  coated  
with  gold-palladium  under  an  argon  atmosphere  at   
room  temperature  and  then  the  surface morphology  
of  the  microsponges  can  be  studied  by  scanning  
electron  microscopy  (SEM). SEM  of  a  fractured   
microsponge  particle  can  also  be  taken  to  illustrate  
its  ultra  structure.  
 Determination of Loading Efficiency and 
production yield: The loading efficiency (%) of the 
microsponges can be calculated according to the 
following equation:  
                    
                                 
                        
     
 Production Yield: The production yield of the 
microparticles can be determined by calculating 
accurately the initial weight of the raw materials and 
the last weight of the microsponge obtained.       
                  
                             
                                 
     
 Compatibility Studies: Compatibility of drug with 
reaction adjuncts can be studied by thin layer 
chromatography (TLC) and Fourier Transform Infra-
red spectroscopy (FT-IR). Effect of polymerization on 
crystallinity of the drug can be studied by powder X-
ray diffraction (XRD) and Differential Scanning 
Colorimetry (DSC). For  DSC approximately 5mg 
samples can be accurately weighed into aluminium 
pans and sealed and can be run at a heating rate of 
15 /min over a temperature range 25–430  in 
atmosphere of nitrogen.  
 Resiliency (viscoelastic propertie): Resiliency 
(viscoelastic properties) of microsponges can be 
modified to produce beadlets that is softer or firmer 
according to the needs of the final formulation. Increased 
cross-linking tends to slow down the rate of release. 
Hence resiliency of microsponges will be studied and 
optimized as per the requirement by considering release 
as a function of cross-linking with time.  
 Dissolution Studies: Dissolution profile of 
microsponges can be studied by use of dissolution 
apparatus (USP XXIII) with a modified basket consisted 
of 5µm stainless steel mesh. Speed of the rotation is 150 
rpm. The dissolution medium is selected while 
considering solubility of actives to ensure sink 
conditions. Samples from the dissolution medium can be 
analyzed by suitable analytical method at various 
intervals. 
 Dissolution kinetics release: In order to investigate the 
mode of release from the microsponges, the release data 
of optimized formulation was analyzed with the 
following mathematical models: 
 Zero order kinetics: 
The equation for zero order kinetic is represented as; 
K0t=W0-Wt----------------------------- (4) 
Where, 
W0 = initial amount of drug 
Wt= amount of drug at time t 
K0=zero order release constant 
 First order kinetics: 
The equation for zero order kinetic is represented as; 
logQt= logQo+
   
     
--------------------------     
Where, 
Qt= amount of drug released in time t 
Q0= initial amount of drug 
K1= first order release constant 
 Higuchi model: 
The simplified Higuchi equation is represented as; 
Qt = KHt1/2------------------------------------------ (6) 
Where,  
Qt= amount of drug released in time t 
KH = Higuchi’s constant 
A linear relationship between amount of drug released (Q) 
versus square root of time (t1/2) is observed if the drug 
release from the matrix is diffusion controlled. 
 Hixson-Crowell model: 
The simplified equation is represented as; 
W01/3-Wt1/3=Kt----------------------------- (7) 
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Where,  
W0=initial amount of drug  
Wt= remaining amount of drug at time t 
K= cube root constant. 
 Korsmeyer- Peppas model: 
The Korsmeyer-Peppas model relates drug release 
exponentially to time. It is described by the following 
equation;  
  
  
     ------------------------------------ (8) 
Where,  
Mt/M∞ = fractional release of drug 
a = constant incorporating structural and geometric 
characteristics of the drug dosage form 
n= release exponent 
The value of n indicates the drug release mechanism. This 
model is used to analyze the release of drug from polymeric 
dosage forms, when the release mechanism is not well 
known or when there is a possibility of more than one type 
of release mechanisms are involved. 
 Determination of true density:  
The true density of microparticles is measured using an 
ultra-pycnometer under helium gas and is calculated from a 
means of repeated determinations. 
 Characterization of pore structure:  
Pore volume and diameter are vital in controlling the 
intensity and duration of effectiveness of the active 
ingredient. Pore diameter also affects the migration of active 
ingredients from microsponges into the vehicle in which the 
material is dispersed. Mercury intrusion porosimetry can be 
employed to study effect of pore diameter and volume with 
rate of drug release from microsponges. Porosity parameters 
of microsponges such as intrusion–extrusion isotherms, 
pore size distribution, total pore surface area, average pore 
diameters, interstitial void volume, percent porosity, percent 
porosity filled, shape and morphology of the pores, bulk and 
apparent density can be determined by using mercury 
intrusion porosimetry. [22,23,24] 
RELEASE MODULATION 
In general, microsponges retard the release of the drug. 
Various groups have studied the release of actives from such 
systems. Some studies have shown an improved rate of 
release by increasing the active/polymer ratio and lowering 
the polymer wall thickness; however these results are not 
supported by another set of studies. Thus, there seem to be 
many other factors affecting the release of the drug from the 
microsponges. Another important parameter that governs 
the release seems to be the pore diameter. However, another 
study has shown that even the overall porosity (including 
the pore diameter and the number of pores) also affects the 
drug release. 
SAFETY CONSIDERATIONS 
Safety studies of microsponges can be confirmed by: 
 Allergenicity in guinea pigs. 
 Eye irritation studies in rabbits. 
 Mutagenicity in bacteria. 
 Oral toxicity studies in rats. 
 Skin irritation studies in rabbits. 
Microsponges are mainly used for topical and recently for 
oral administration as well as biopharmaceutical delivery. It 
offers the formulator a range of alternatives to develop drug 
and cosmetic products. These are developed to deliver an 
active ingredient efficiently at the low dose and also to 
enhance stability, reduce side effects and modify drug 
release. [7] 
UTILIZATION OF MICROSPONGES IN 
PHARMACEUTICAL INDUSTRY 
Microsponge delivery systems are used to enhance the 
safety, effectiveness and aesthetic quality of topical 
prescription, over-the-counter and personal care products. 
Microsponges can be used in variety of applications. It is 
used mostly for topical and recently for oral administration. 
Several patents have reported that it can be used as an 
excipient due to its high loading capacity and sustained 
release ability. It offers the formulator a range of alternatives 
to develop drug and cosmetic products. Microsponges are 
designed to deliver a pharmaceutical active ingredient 
efficiently at the minimum dose and also to reduce side 
effects, also enhance stability and modify drug release. Over-
the-counter products that incorporate microsponge drug 
delivery system include numerous sunscreens, specialized 
rejuvenated products, and moisturizers. 
1. Microsponge for topical delivery  
The Microsponge systems are based on microscopic, 
polymer based microspheres that can bind, suspend or 
entrap a wide variety of substances and then be 
incorporated into a formulated product, such as a gel, cream, 
liquid or powder. A single Microsponge is as tiny as a 
particle of talcum powder, measuring less than one-
thousandth of an inch in diameter. Like a true sponge, each 
microsphere consists of a myriad of interconnecting voids 
within a non-collapsible structure that can accept a wide 
variety of substances. The outer surface is typically porous, 
allowing the controlled flow of substances into and out of 
the sphere. Several primary characteristics, or parameters, 
of the Microsponge system can be defined during the 
production phase to obtain spheres that are tailored to 
specific product applications and vehicle compatibility. 
Microsponge systems are made of biologically inert 
polymers. Extensive safety studies have demonstrated that 
the polymers are non-irritating, non- mutagenic, non-
allergenic, non-toxic and non-biodegradable. As a result, the 
human body cannot convert them into other substances or 
break them down. Although they are microscopic in size, 
these systems are too large to pass through the stratum 
corneum when incorporated into topical products. Benzoyl 
peroxide (BPO) is commonly used in topical formulations for 
the treatment of acne, with skin irritation as a common side 
effect. It has been shown that controlled release of BPO from 
a delivery system to the skin could reduce the side effect 
while reducing percutaneous absorption. Therefore, 
microsponge delivery of Benzoyl peroxide was developed 
using an emulsion solvent diffusion method by adding an 
organic internal phase containing benzoyl peroxide, ethyl 
cellulose and dichloromethane into a stirred aqueous phase 
containing polyvinyl alcohol and by suspension 
polymerization of styrene and divinyl benzene. The 
prepared microsponges were dispersed in gel base and 
microsponge gels are evaluated for anti-bacterial and skin 
irritancy. The entrapped system released the drug at slower 
rate than the system containing free BPO. Topical delivery 
system with reduced irritancy was successfully developed. 
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2. Microsponge for oral delivery:  
In oral applications, the microsponge system has been 
shown to increase the rate of solubilisation of poorly water 
soluble drugs by entrapping such drugs in the microsponge 
system's pores. As these pores are very small, the drug is in 
effect reduced to microscopic particles and the significant 
increase in the surface area thus greatly increases the rate of 
solubilisation. Controlled oral delivery of ibuprofen 
microsponges is achieved with an acrylic polymer, Eudragit 
RS, by changing their intraparticle density. Sustained release 
formulation of chlorpheniramine maleate, using powder-
coated microsponges, is prepared by the dry impact 
blending method, for oral drug delivery. Controlled oral 
delivery of Ketoprofen prepared by quasi-emulsion solvent 
diffusion method with Eudragit RS 100 and afterwards 
tablets of microsponges were prepared by the direct 
compression method. Results indicated that compressibility 
was much improved in the physical mixture of the drug and 
polymer; due to the plastic deformation of the sponge-like 
microsponge structure, producing mechanically strong 
tablets. Colon-specific, controlled delivery of Flurbiprofen 
was conducted by using a commercial Microsponge 5640 
system. In vitro studies exhibited that compression-coated 
colon-specific tablet formulations started to release the drug 
at the eighth hour, corresponding to the proximal colon 
arrival time, due to addition of the enzyme, following a 
modified release pattern, while the drug release from the 
colon-specific formulations prepared by pore plugging the 
microsponges showed an increase at the eighth hour, which 
was the point of time when the enzyme addition was made. 
3. Microsponge for Bone and Tissue Engineering:  
Bone-substitute Compounds were obtained by mixing pre 
polymerized powders of polymethyl methacrylate and liquid 
methyl methacrylate monomer with two aqueous 
dispersions of tricalcium phosphate grains and calcium 
deficient hydroxyapatite powders. The final composites 
appeared to be porous and acted as microsponges. Basic 
fibroblast growth factor (bFGF) incorporated in a collagen 
sponge sheet was sustained released in the mouse sub-cutis 
according to the biodegradation of the sponge matrix, and 
exhibited local angiogenic activity in a dose-dependent 
manner. The injection of collagen microsponges 
incorporating bFGF induced a significant increase in the 
blood flow, in the murine ischemic hind limb, which could 
never have been attained by the bolus injection of bFGF. 
These results suggest the significance and therapeutic utility 
of the type I collagen as a reservoir of bFGF. [25] 
RECENT IMPROVEMENT IN MICROSPONGE DRUG 
DELIVERY SYSTEM 
Various advances were made by modifying the methods to 
form Nanosponges, nanoferrosponges and porous micro 
beads. β - CD nanosponges were also developed that can be 
used for hydrophobic as well as hydrophilic drugs, in 
contrast to polymeric micro or nanosponges. These 
advanced systems were studied for oral administration of 
dexamethasone, Flurbiprofen, doxorubicin hydrochloride, 
itraconazole and serum albumin as model drug. These 
nanosponges were developed by cross- linking the β CD 
molecule by reacting the β-CD with biphenyl carbonate. 
Some researchers also observed the nanosponges as good 
carrier for the delivery of gases. Researchers also observed 
that incorporating a cytotoxic in a nanosponge carrier 
system can increase the potency of the drug suggesting that 
these carriers can be potentially used for targeting the 
cancerous cells.[6] 
FUTURE PROSPECTS 
Microsponge drug delivery system holds a promising 
opportunity in various pharmaceutical applications in the 
upcoming future as it has unique properties like enhanced 
product performance and elegancy, extended release, 
improved drug release profile, reduced irritation, improved 
physical, chemical and thermal stability which makes it 
flexible to develop novel product forms. The real challenge 
in future is the development of the delivery system for the 
oral peptide delivery by varying ratio of polymers. The use 
of bioerodible and biodegradable polymers for the drug 
delivery is facilitating it for the safe delivery of the active 
material. As these porous systems have also been studied for 
the drug delivery through pulmonary  route which shows 
that these system can show effective drug release even in the 
scarce of the dissolution fluid thus colon is an effective site 
for targeting for drug release. These carriers also require to 
be developed for alternative drug administration routes like 
parenteral and pulmonary route. These particles can also be 
used as the cell culture media and thus can also be employed 
for stem cell culture and cellular regenaration in the body. 
Due to their elegance, these carrier systems have also found 
their application in cosmetics. These developments enabled 
researchers to utilize them variably. These novelties in 
formulation also open new ways for drug delivery. [26] 
 
Table 2: Marketed products based on microsponge delivery system: [27] 
Product Name  Pharmaceutical Uses Manufacturer 
Carac Cream, 0.5% Actinic keratoses Dermik Laboratories, Inc 
Glycolic Acid Moisturizer w/SPF 15 Anti-Wrinkles, soothing AMCOL Health & Beauty Solution 
Line Eliminator Dual Retinol Facial Treatment Anti-Wrinkles Avon 
Retin A Micro Acne vulgaris Ortho-McNeil Pharmaceutical, Inc. 
Retinol 15 Night cream Anti-wrinkles Sothys 
EpiQuin Micro Hyper pigmentation SkinMedica Inc 
Retinol cream Helps maintain healthy skin Biomedic 
Sports cream RS and XS Anti-inflammatory Embil Pharmaceutical Co. Ltd. 
Salicylic Peel 20 Excellent exfoliation Biophora 
Oil free matte block SPF 20 Sunscreen Dermalogica 
Dermalogica Oil Control Lotion Skin protectant John and Ginger Dermalogica Skin Care 
Products 
Ultra Guard Protects baby‟s skin Scott Paper Company 
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RECENT RESEARCH ON MICROSPONGE DRUG DELIVERY SYSTEM: [28-32] 
Several studies reported the formulation and evaluation of Microsponge loaded drugs for different purposes. Recent research 
on microsponge drug delivery system is summarized in (Table 3).  
Table 3: Summary of Recent Research on Microsponge Drug Delivery System. 
 
DRUG  
 
METHOD USED 
 
EXCIPIENT USED 
 
RESULT  
Prednisolone Quasi-emulsion solvent 
diffusion method 
Eudragit RS-100, 
Triethylcitrate, polyvinyl 
alcohol 
The in-vitro dissolution studies of 
microsponges in the media with different ph 
(1.2, 7.4 and 6.8) showed that drug release in 
colon could be controlled by Eudragit RS 100 
Oxybenzone Quasi-emulsion solvent 
diffusion method 
Ethyl cellulose-N10,  
Polyvinyl alcohol, Hydroxy 
propyl methyl cellulose.            
In vitro and ex vivo study revealed enhanced 
topical dichloromethane, retention of drug and 
increased methanol 
Valsartan Quasi-emulsion solvent 
diffusion method 
Ethyl cellulose, polyvinyl 
alcohol, Hydroxy propyl 
methyl cellulose.            
Increase in the ratio of the drug: polymer and 
stirring rate resulted the cumulative 
percentage drug release up to 8 hrs 
Naproxen Quasi-emulsion solvent 
diffusion method 
Eudragit RS-100,        
carbopol, polyvinyl alcohol   
Increase in the ratio of the drug: polymer, 
Resulted control release rate 
Diclofenac 
Diethylamine    
Quasi-emulsion solvent 
diffusion method 
Eudragit RS 100,                                       
sodium alginate,                                         
dibutyl phthalate, 
Extended drug release (75.88% at 8 h)                                   
 
CONCLUSION 
From the above study, it is concluded that the microsponges 
have the ability to include hydrophobic drugs and release 
them in a controlled manner and predictable manner in the 
targeted site of the body. Microsponge delivery systems are 
considered as a promising carrier for the controlled release 
and targeted release of many topical and oral active agents 
as well as biopharmaceutical drug delivery. Microsponge 
drug delivery system is innovative and creative techniques 
to deliver active agents, they can realize the full capacities of 
these different materials providing improved safety, 
increased strength, reduce side effects of active 
pharmaceutical drug delivery system. It also enhanced 
flexibility and improved active pharmaceutical ingredient 
compatibility.  Microsponge delivery system can be an 
acceptable approach for a new generation of Pharmaceutical 
and Cosmetic industry. Microsponge formulations are self-
sterilizing as their average pore size is 0.25 μm where 
bacteria cannot penetrate, they can be developed with 
prolonged stability without the use of preservatives. The 
porous structure of microsponge their ability to release their 
active ingredients in a controlled manner. 
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